A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
National Cancer Institute (NCI)
Kahr Medical
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Genentech, Inc.
Replimune Inc.
ImmunityBio, Inc.
University of Pittsburgh
Gruppo Oncologico del Nord-Ovest
Cancer Research UK
Exelixis
University of Colorado, Denver
Vall d'Hebron Institute of Oncology
Exelixis
Genentech, Inc.
AIO-Studien-gGmbH
University of Texas Southwestern Medical Center
Seattle Project Corporation
University of Iowa
Kahr Medical
Gritstone bio, Inc.
Exelixis
Keythera (Suzhou) Pharmaceuticals Co. Ltd
The Netherlands Cancer Institute
Academic and Community Cancer Research United
Hoffmann-La Roche
Amgen
Hoffmann-La Roche
Asan Medical Center
Hoffmann-La Roche
Gruppo Oncologico del Nord-Ovest
Fate Therapeutics
Federation Francophone de Cancerologie Digestive
Fate Therapeutics
Hoffmann-La Roche
Hoffmann-La Roche
Duke University